Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreement Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic…